Prelude Therapeutics, Inc. PRLD

Alliance Global analyst James Molloy said SLS009, which is being developed for acute myeloid leukemia, could potentially be used to treat additional cancers.

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026 Enrollment continues in Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) Current cash runway expected into the

Prelude Therapeutics Incorporated (NASDAQ:PRLD) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 15, 2026, Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeutics Incorporated (NASDAQ:PRLD) with an Early-Stage Biotech rating. Johnson said the company’s “differentiated approach” in metastatic breast cancer could unlock a $10B opportunity. On May 12, […]

Last week, you might have seen that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) released its quarterly result to...

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026 Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026 Appo

Prelude Therapeutics (NASDAQ:PRLD) is one of the best biotech penny stocks to buy in 2026. On April 20, Prelude Therapeutics presented promising preclinical data for PRT13722, a first-in-class, oral KAT6A degrader. Designed for HR+/HER2- breast cancer, the candidate demonstrated the ability to achieve complete tumor regressions as a monotherapy across multiple models, including those resistant […]

Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer Prelude Remains on Track to File Investigational New Drug (IND) Application by mid-2026 and to initiate clinical trial in 2H 2026 WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced the presentation of new preclinical data fro